The combination of a strong EPS beat, reduced cash burn, and a $40M financing facility significantly de-risks the near-term dilution risk and extends runway through key SENTI-202 pivotal trial milestones. The positive FDA feedback on a single-arm pivotal trial is a major catalyst — watch for enrollment updates and potential partnership interest. The stock's small market cap ($30M) amplifies sensitivity to these binary pipeline events.
Price Chart
Executive Summary
Senti Bio reported Q1 2026 EPS of -$0.14, beating consensus of -$0.36 by 61%, on minimal revenue of $16K. The beat is driven by a $6.9M non-recurring lease modification gain and reduced operating expenses. More importantly, the company secured a strategic financing vehicle for up to $40M (initial $10M tranche) and received positive FDA feedback supporting a single-arm pivotal trial for SENTI-202 in R/R AML, extending the cash runway and de-risking the regulatory path.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.14 vs consensus -$0.36 (beat by 61%)
- Net loss narrowed to $4.2M from $14.1M YoY, driven by $6.9M lease modification gain and lower R&D/G&A spend
- Cash and equivalents $8.9M as of March 31, 2026, down from $16.4M at year-end 2025
- Secured up to $40M strategic convertible note financing (initial $10M tranche expected to close May 2026)
- Positive FDA Type B RMAT meeting outcome supports single-arm pivotal trial design for SENTI-202 in R/R AML
- Identified Donor X attribute correlated with 50% composite CR rate in Phase 1; will be used in all future manufacturing
- Operating cash burn reduced to $7.5M in Q1 2026 vs $14.1M in Q1 2025
Financial Impact
EPS beat of 61% vs consensus; net loss improved by $9.9M YoY; cash runway extended by up to $40M financing
Risk Factors
- Cash burn continues; $8.9M cash on hand may require additional financing before the $40M facility is fully drawn
- SENTI-202 pivotal trial enrollment and results remain binary and uncertain
- Dilution risk from convertible note conversion if stock price appreciates
- Non-recurring lease modification gain ($6.9M) inflates reported net loss improvement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294967 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.1720 | awaiting T+5 | — | $0.1867 (−8.55%) |
Oct 13, 2026 14d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1867 (−22.47%) |
Oct 13, 2026 14d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1867 (+22.47%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1867 (+43.30%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1867 (+43.30%) |
Sep 22, 2026 5w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1867 (+40.84%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1867 (+38.99%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1867 (−43.87%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1867 (+43.87%) |
Aug 20, 2026 9w ago | 8-K | $0.3886 $0.3770 | ▲ +2.99% | ▲ +3.46% | $0.1867 (+51.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers